Table 1

 Baseline characteristics of participants

Leflunomide or placebo (n = 45)Etanercept (n = 10)
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASG, Bath Ankylosing Spondylitis Global; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HDLc, high-density lipoprotein cholesterol; TC, total cholesterol.
*Values are mean (SD) or median (interquartile range), as applicable.
Demographic features
    Age (years)42 (11)41 (10)
    Sex (male:female)32:139:1
Disease activity parameters
    BASG6.4 (1.8)6.7 (1.6)
    BASFI5.3 (1.8)4.4 (1.9)
    BASDAI5.5 (1.4)4.9 (1.2)
    ESR (mm/h)15 (10–31)*37 (13–49)*
    CRP (mg/l)13 (4–40)*11 (4.4–29.4)*
Lipids
    TC (mmol/l)4.9 (1.2)4.4 (0.8)
    HDLc (mmol/l)1.1 (0.9–1.4)*1.3 (0.3)
    Atherogenic index4.3 (3.1–5.5)*3.7 (1.1)
    Triglycerides (mmol/l)1.2 (0.8–1.8)*1.1 (0.7–1.6)*